

# Clinical Impact of Genetics in Sensorineural hearing Loss

Dylan K. Chan, MD, PhD

Associate Professor  
Pediatric Otolaryngology-Head and Neck Surgery  
Benioff Children's Hospital  
University of California, San Francisco

Susan Wiley, MD

Professor  
Developmental & Behavioral Pediatrics  
Cincinnati Children's Hospital Medical Center  
University of Cincinnati

EHDI Conference  
March 15, 2022  
2:30-3:00 pm MST


# Conflict of Interest

- The presenters have no conflicts of interest

# Outline


- Genetic testing in children who are D/HH
- The impact of genetic knowledge on management of D/HH
- Case studies
- Questions

# Genetic Testing Who? When?



Liming et al., IPOG  
Consensus Statement,  
2016

# Genetic Testing Who? When?



Liming et al., IPOG  
Consensus Statement,  
2016

# Genetic Testing How?



Molecular Otolaryngology/Resonance Laboratories  
The University of Iowa • 5270 CB88 • Iowa City, IA 52242-1078  
319-335-6623 Tel • 319-353-5869 Fax • <https://mrcr.labs.uoiowa.edu/>  
CUIA: 1600966193

OtoSCOPE<sup>®</sup>  
GENETIC TESTING  
Version 9 (224 genes)

Gene	Hearing Loss Phenotypes	OMIM Gene ID	Inheritance
ADH22	Polychaeropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHMAC syndrome)	616339	AR
ACTB	Baraitser-Winter syndrome 1	102549	AD
ACTG1	Deafness, autosomal dominant 20/Baraitser-Winter syndrome 2	102560	AD
ADCY1	Deafness, autosomal recessive 44	103077	AR
ADGRV1	Usher syndrome type 2C	602824	AR
AHAT1	Autism, neurotypical, X-linked 1/Deafness, X-linked 5	305103	XLR
ALAS1	Albinism syndromes	606848	AR
AMFR1	Mitochondrial cytochrome b, hearing impairment, elliptocytosis, and nephrocalcinosis	100136	XLR
AMN1	Caerleonophthalmic dysplasia	602195	AD
ATP2B2	Deafness, autosomal dominant*	109133	AD
ATP2B4	Renal tubular acidosis, distal, 1, with or without sensorineural hearing loss	602193	AR
ATP2B1	Renal tubular acidosis, distal, 2, with progressive sensorineural hearing loss	103132	AR
ATP2B2	Deafness, congenital, with Orchocheirachy, autosomal dominant (DODD syndrome)	602193	AD
BSCL1	Pigmented syndrome	604647	AR
DEAF1	Deafness, autosomal recessive 112	602011	AR
DFND	Deafness, autosomal recessive 73/Deafness syndrome type 4A	602032	AR
DFN1	Retinitis pigmentosa	602033	AR
DFNB2	Deafness, autosomal recessive 93	607344	AR
DFNB10	Sensorineural deafness and blindness (SAMD)	149155	AR
DFNB29	Deafness, autosomal dominant 44	610081	AD
DFNB4	Deafness, autosomal dominant 66	601956	AD
DFNB6A	Deafness, autosomal recessive 105/Deafness, autosomal recessive 32/Hearing impairment infantile male syndrome	605001	AR
DFNB23	Deafness, autosomal recessive 12/Usher syndrome type 1D	605386	AR
DFNB16	Deafness, autosomal dominant 40/Deafness, autosomal recessive 113	619531	AD/AR
DFNB8	Cone-rod dystrophy and hearing loss 1	617130	AR
DFNB7	CHARGE syndrome	609832	AD
DFNB3	Torrey's presenile brachydactyly syndrome	608183	AR
DFNB2	Deafness, autosomal recessive 48	607674	AR
DFNB2	Williams syndrome 2	618507	AR
DFNB4	Deafness, autosomal recessive 29	604004	AR
DFNB9	Deafness, autosomal recessive*	606729	AR
DFNB5	Deafness, autosomal recessive 103	607018	AR
DFNB	Preaxial syndrome type 3	601133	AR
DFNB1	Usher syndrome type 3A	606337	AR
DFNB	Deafness, autosomal dominant 9/Deafness, autosomal recessive 110	601136	AD/AR
CD11A1	Deafness, autosomal dominant 17/Sickler syndrome type 2/Blue-ball syndrome	132190	AD
CD11A2	Deafness, autosomal recessive 53/Deafness, autosomal dominant 13/Sickler syndrome type 1/Ortopolydysparemia/dysplasia, autosomal dominant/Ortopolydysparemia/dysplasia, autosomal recessive	132030	AD/AR
CD101	Sickler syndrome 1	130180	AD
CD103	Alport syndrome 2, autosomal recessive/Alport syndrome 3, autosomal dominant	130180	AD/AR
CD104	Alport syndrome 2, autosomal recessive	130181	AR
CD105	Alport syndrome 1, X-linked	303630	XLR
CD106	Deafness, X-linked 6	303631	XLR
CD101	Sickler syndrome 4	130182	AR
CD102	Sickler syndrome 5	130200	AR
CD103	Sickler syndrome	130200	AR
DFNB	Deafness, autosomal dominant 40	171740	AD
DFNB17	Woodhouse-Sakab syndrome	612536	AR
DFNB22	Deafness, autosomal recessive 66	606795	AR
DFNB10	Deafness, autosomal dominant 64	602193	AD
DFNB11	Deafness, autosomal dominant 1, with or without thrombocytopenia	602121	AD
DFNB12	Autism, neurotypical, autosomal dominant, 1	619567	AD
DFNB5	Spide-Bradford malformation 1 with sensorineural hearing loss	602028	AD/AR
DFNB22	Deafness, autosomal dominant 71	617186	AD
DFNB71	Cerebellar ataxia, deafness, and neuropathy, autosomal dominant/Neuropathy, hereditary sensory, type 1E (HMSN 1, neuropathic)	135375	AD
DFNB	Deafness, autosomal dominant 39 with dentogoniosis/improfects	135486	AD

## Single Gene/Targeted Panels

- GJB2
- Pendred, Ushers

## Comprehensive hearing-loss panels

120-220 genes

- Targeted capture/massively parallel sequencing
- Deletion/duplication analysis
- Copy number analysis

Otoscope (U of Iowa)

GeneDx

Invitae

Multiple others

Cheek swab or blood test

# Genetic Testing Why?

Any cause identified

Genetic counseling, education, acceptance

Specific genes/variants


Hearing expectations: progression, ototoxicity, cochlear implant outcomes

Future management options

Cochlear implantation, gene therapy

Syndromic association identified

Early screening for associated differences



# Genetic Testing Why?

Any cause identified

Genetic counseling, education, acceptance

Specific genes/variants

Hearing expectations: progression, ototoxicity, cochlear implant outcomes

Future management options

Cochlear implantation, gene therapy

Syndromic association identified

Early screening for associated differences



# Genetic Testing Why?

111 children with SNHL

Genetic testing before hearing aid evaluation


73% Underrepresented minorities

67% Publicly insured

20% Genetic diagnosis

Receiving a genetic diagnosis associated with increased likelihood to be fit with HA

Adjusted for hearing level, insurance, race/ethnicity



Brodie and Chan, unpublished

# Genetic Testing Why?

Any cause identified

Genetic counseling , education, acceptance

Specific genes/variants

Hearing expectations: progression, ototoxicity, cochlear implant outcomes

Future management options

Cochlear implantation, gene therapy

Syndromic association identified

Early screening for associated differences




# Genetic Testing Progressive Hearing Loss

## Progressive

SLC26A4  
TECTA  
Taperin  
Mir95

## (Mostly) Non-progressive

GJB2  
STRC  
OTOG



# Genetic Testing Management Outcomes

## Auditory Neuropathy Spectrum Disorder (ANSD)

Highly variable presentation and outcomes

Common etiologies:

1) Cochlear nerve deficiency

Poor cochlear implant outcomes

Recommend ASL

2) Otoferlin variants (hair cell/neuron synapses)

Excellent cochlear implant outcomes

Impending gene therapy



# Genetic Testing Why?

Any cause identified

Genetic counseling , education, acceptance

Specific genes/variants


Hearing expectations: progression, ototoxicity, cochlear implant outcomes

Future management options

Cochlear implantation, gene therapy

**Syndromic association identified**

Early screening for associated differences



# Genetic Testing **Syndromic Discovery**



SLC26A4	Pendred
CDH23, Myo7a, USH2A...	Usher
COL11A1, COL11A2...	Stickler
COL4A3, COL4A4...	Alport
STRC/CATSPER	Deafness/infertility
EDN3, MITF, PAX3...	Waardenburg
EYA1, SIX5	Branchio-oto-renal
GATA3	Barakat

~3-5% of hearing-loss gene panels reveal a previously-unrecognized syndromic association

# Genetic testing in children who are D/HH: looking beyond the ear

- Genetic testing alone does not replace the importance of an evaluation by a clinical geneticist
- Importance of dysmorphology: recognition of syndromes associated with hearing differences
- Among children who are Deaf/HH with an intellectual disability or autism spectrum disorder, we should not stop our genetic work-up at the level of the ear



# Genetic testing in children who are D/HH: looking beyond the ear

- Broader genetic evaluation, following the standard of care for work-up of developmental disabilities is important to remember
  - 3 generation family history, dysmorphology,
  - microarray, Fragile X, PTEN (macrocephaly), MECP2 (in girls), expanded genetic panels
  - Recognition of multiple congenital anomalies
  - Technology and knowledge is ever changing!

## Consensus Statement: Chromosomal Microarray Is a First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or Congenital Anomalies

David T. Miller,<sup>1\*</sup> Margaret P. Adam,<sup>2,3</sup> Swaroop Aradhya,<sup>4</sup> Leslie G. Biesecker,<sup>5</sup> Arthur R. Brothman,<sup>6</sup> Nigel P. Carter,<sup>7</sup> Deanna M. Church,<sup>8</sup> John A. Crolla,<sup>9</sup> Evan E. Eichler,<sup>10</sup> Charles J. Epstein,<sup>11</sup> W. Andrew Faucett,<sup>2</sup> Lars Feuk,<sup>12</sup> Jan M. Friedman,<sup>13</sup> Ada Hamosh,<sup>14</sup> Laird Jackson,<sup>15</sup> Erin B. Kaminsky,<sup>2</sup> Klaas Kok,<sup>16</sup> Ian D. Krantz,<sup>17</sup> Robert M. Kuhn,<sup>18</sup> Charles Lee,<sup>19</sup> James M. Ostell,<sup>8</sup> Carla Rosenberg,<sup>20</sup> Stephen W. Scherer,<sup>21</sup> Nancy B. Spinner,<sup>17</sup> Dimitri J. Stavropoulos,<sup>22</sup> James H. Tepperberg,<sup>23</sup> Erik C. Thorland,<sup>24</sup> Joris R. Vermeesch,<sup>25</sup> Darrel J. Waggoner,<sup>26</sup> Michael S. Watson,<sup>27</sup> Christa Lese Martin,<sup>2</sup> and David H. Ledbetter<sup>2,\*</sup>

## Original Investigation

## Molecular Diagnostic Yield of Chromosomal Microarray Analysis and Whole-Exome Sequencing in Children With Autism Spectrum Disorder

Kristina Tammimies, PhD; Christian R. Marshall, PhD; Susan Walker, PhD; Gaganjot Kaur, MRes; Bhooma Thiruvahindrapuram, MSc; Anath C. Lionel, PhD; Ryan K. C. Yuen, PhD; Mohammed Uddin, PhD; Wendy Roberts, MD; Rosanna Weksberg, MD-PhD; Marc Woodbury-Smith, MD-PhD; Lonnie Zwaigenbaum, MD; Evdokia Anagnostou, MD; Zhuozhi Wang, PhD; John Wei, PhD; Jennifer L. Howe; Matthew J. Gazzellone, MSc; Lynette Lau, MSc; Wilson W. L. Sung, MSc; Kathy Whitten; Cathy Vardy, MD; Victoria Crosbie, MD; Brian Tsang, BSc; Lia D'Abate, BSc; Winnie W. L. Tong; Sandra Luscombe, MD; Tyna Doyle, MD; Melissa T. Carter, MD; Peter Szatmari, MD; Susan Stuckless, PhD; Daniele Merico, PhD; Dimitri J. Stavropoulos, PhD; Stephen W. Scherer, PhD; Bridget A. Fernandez, MD

The American Journal of Human Genetics 2010

86, 749–764



JAMA 2015 314(9):895-903



# Impact of Genetic Knowledge on the management of children who are D/HH: broad-based genetic testing

- Goals of understanding genetic etiology:
- Recurrence risk for the individual, parents, siblings
- Associated medical conditions that may have been unrecognized



# Case Studies

- a. Non-syndromic SNHL (GJB2) - Dylan
- b. Syndromic SNHL (Usher syndrome) - Dylan
- c. Developmental delay + SNHL - Susan

# Case 1: CC

	LEFT EAR (dBeHL)	RIGHT EAR (dBeHL)
500 Hz tone burst ABR	15	15
1000 Hz tone burst ABR	15	30
2000 Hz tone burst ABR	15	35
4000 Hz tone burst ABR	15	25

2 mo old M  
Full term  
CMV negative  
Club foot  
No FH of hearing loss

Family uncertain of ABR findings  
Declined Early Start and amplification

# Case 1: CC

2 mo old M  
Full term  
CMV negative  
Club foot  
No FH of hearing loss

Family uncertain of ABR findings  
Declined Early Start and amplification

	LEFT EAR (dBeHL)	RIGHT EAR (dBeHL)
500 Hz tone burst ABR	15	15
1000 Hz tone burst ABR	15	30
2000 Hz tone burst ABR	15	35
4000 Hz tone burst ABR	15	25

Result(s): **POSITIVE**

GENE	MODE OF INHERITANCE	VARIANT	ZYGOSITY	CLASSIFICATION
GJB2	Autosomal dominant, Autosomal recessive	c.109 G>A p.(V37I)	Homozygous	Pathogenic Variant

# Case 1: CC

	LEFT EAR (dBeHL)	RIGHT EAR (dBeHL)
500 Hz tone burst ABR	15	15
1000 Hz tone burst ABR	15	30
2000 Hz tone burst ABR	15	35
4000 Hz tone burst ABR	15	25

2 mo old M  
Full term  
CMV negative  
Club foot  
No FH of hearing loss

Family uncertain of ABR findings  
Declined Early Start and amplification


Result(s): **POSITIVE**

GENE	MODE OF INHERITANCE	VARIANT	ZYGOSITY	CLASSIFICATION
GJB2	Autosomal dominant, Autosomal recessive	c.109 G>A p.(V37I)	Homozygous	Pathogenic Variant

Genetics corroborates ABR  
Rules out syndromic association


Enrolled in Early Start  
Fit with R hearing aid

# Case 2: LP



3 wk old F  
Full term  
CMV negative  
MRI normal  
Otherwise healthy  
No FH of hearing loss

# LP: Genetic Testing




3 wk old F  
 Full term  
 CMV negative  
 MRI normal  
 Otherwise healthy  
 No FH of hearing loss

## POSITIVE

Gene	Coding DNA	Variant	Zygoty	Classification
MYO7A	c.494 C>T	p.Thr165Met (T165M)	Heterozygous	Pathogenic Variant
MYO7A	c.321_322insA	p.Tyr108IlefsX32 (Y108IfsX32)	Heterozygous	Pathogenic Variant

# LP: Genetic Testing **Myo7A**




- NS-SNHL (DFNB2)
- Usher1B
- c.494 C>T: Usher1B
- c.321\_322insA: unknown
- Parental testing confirms *trans*
- Ophthalmology referral
  - Normal ophtho exam
  - EUA: retinal dystrophy, maculopathy

## POSITIVE

Gene	Coding DNA	Variant	Zygoty	Classification
MYO7A	c.494 C>T	p.Thr165Met (T165M)	Heterozygous	Pathogenic Variant
MYO7A	c.321_322insA	p.Tyr108IlefsX32 (Y108IlefsX32)	Heterozygous	Pathogenic Variant

# LP: Genetic Testing **Myo7A**



- Bilateral cochlear implantation
  - 6 months
  - Age-appropriate speech & language
- Ophthalmologic monitoring
  - Gene therapy (Sanofi NCT01505062)

---

## Genetic Testing Leading to Early Identification of Childhood Ocular Manifestations of Usher Syndrome

---

Kara D. Brodie, MD, MPhil ; Anthony T. Moore, BM, BCh, FMedSci; Anne M. Slavotinek, MBBS, PhD; Anna K. Meyer, MD; Garani S. Nadaraja, MD; David E. Conrad, MD; Jacqueline E. Weinstein, MD; Dylan K. Chan, MD, PhD

# Case study 3:

- First CI at 18 months and 2<sup>nd</sup> at 3 years
- Age of diagnosis of ID: 4 years of age:
  - Leiter score of 60, Vineland score of 58
- Age of diagnosis of ASD: 7 years of age
  - Evaluation at 4 years, thought to be related to ID rather than ASD, at 7 years, diagnosed with ASD
- Age of Usher Syndrome genetic finding: 10 years of age
  - An ERG at 10 years of age: evidence of early rod-cone degeneration but no functional impairment
  - At 18 years, has not had notable functional vision loss
- At of first seizure: 18 years of age

# Case study 3:

- 5 years of age:
  - **Microarray results:** extra chromosomal material on 10q11.21
  - This region contains no known genes associated with pathology. Thought to most likely a benign copy number variant.
- 10 years of age:
  - **Fragile X testing:** Pre-mutation for Fragile X (CGG repeat size 56)
  - **Hearing gene panel:** genetically confirmed MYO7A gene, compound heterozygote (both parents confirmed to be carriers)
- 13 years of age
  - **Autism/ID expanded panel** negative

# Children don't always follow what's in the books

Dammeyer *Behavioral and Brain Functions* 2012, **8**:16  
<http://www.behavioralandbrainfunctions.com/content/8/1/16>



RESEARCH REPORT

RESEARCH

Open Access

## Hiding in plain sight: genetic deaf-blindness is not always Usher syndrome

Genevieve Medina,<sup>1</sup> Julia Perry,<sup>1</sup> Andrea Oza,<sup>2,3</sup> and Margaret Kenna<sup>1,4</sup>

## Children with Usher syndrome: mental and behavioral disorders

Jesper Dammeyer<sup>1,2</sup>

### Abstract

**Background:** Mental and behavioral disorders among adults with Usher syndrome have been discussed and reported in some case studies but no research has been reported on children with Usher syndrome.

**Methods:** This article investigates the prevalence and characteristics of mental and behavioral disorders among 26 children, 3-17 years of age, with Usher syndrome.

**Results:** Six of the 26 children were diagnosed with a mental or behavioral disorder (1 with schizophrenia and mild mental retardation, 1 with atypical autism and severe mental retardation, 1 with atypical autism and mild mental retardation, 1 with mild mental retardation, and 2 with conduct disorder). Another 3 children had had a mental or behavioral disorder previously in their childhood.

**Conclusion:** Even though vision impairment first manifests in late childhood, some children with Usher syndrome seem to develop mental and behavioral disorders during childhood. The aetiology and treatment of mental and behavioral disorders among children with Usher syndrome are discussed. Children with Usher syndrome and their parents may need clinical support during early childhood to prevent development of mental and behavioral disorders.

**Keywords:** Deafblindness, Dual sensory loss, Mental and behavioral disorders, Usher syndrome, Psychiatry

© 2007 Wiley-Liss, Inc.

American Journal of Medical Genetics Part A 143A:1560–1566 (2007)

## Additional Clinical Manifestations in Children With Sensorineural Hearing Loss and Biallelic *GJB2* Mutations: Who Should Be Offered *GJB2* Testing?

Margaret A. Kenna,<sup>1,2\*</sup> Heidi L. Rehm,<sup>1,3</sup> Caroline D. Robson,<sup>4</sup> Anna Frangulov,<sup>1</sup> Jennifer McCallum,<sup>5</sup> Dinah Yaeger,<sup>5</sup> and Ian D. Krantz<sup>5,6</sup>



# Case study 3

Etiology may or may not be related to other disabilities

Etiology may not protect a child from other reasons for developmental conditions



Just a few examples from my clinical experiences:

- Branchio-oto-renal and XXYY
- GJB2 and Beckwith-Weidemann syndrome (associated with increased risk of tumor)
- GJB2 and Landau-Kleffner syndrome
- GJB and Branchio-oto-renal

“A dog that itches can have ticks and fleas”